CATSHL Syndrome (Camptodactyly, Tall Stature, and Hearing Loss Syndrome): Comprehensive Research Report

1. Disease Information

Overview. CATSHL syndrome — an acronym for CAmptodactyly, Tall Stature, and Hearing Loss — is an ultra-rare skeletal dysplasia/overgrowth syndrome caused by loss-of-function variants in the FGFR3 (fibroblast growth factor receptor 3) gene. It is notable as essentially the phenotypic mirror image of achondroplasia: whereas achondroplasia results from gain-of-function FGFR3 mutations that cause short stature, CATSHL results from loss-of-function FGFR3 mutations that cause tall stature, alongside camptodactyly, scoliosis/chest-wall anomalies, and congenital or early-onset sensorineural hearing loss Toydemir et al., 2006, Am J Hum Genet 79(5):935-941, PMID:17033969.

Key identifiers: - OMIM: #610474 (CATSHLS — CAMPTODACTYLY, TALL STATURE, AND HEARING LOSS SYNDROME) — gene locus FGFR3 (134934) OMIM 610474 - Orphanet: ORPHA:85164 — "Camptodactyly-tall stature-scoliosis-hearing loss syndrome" Orphanet 85164 - MONDO: MONDO:0012504 - Disease Ontology: DOID:0111160 - MedGen/UMLS Concept: C1864852 NCBI MedGen 355844 - Gene:* FGFR3, chromosome 4p16.3; HGNC gene ID for the causal gene

Synonyms: CATSHL syndrome; Camptodactyly–tall stature–hearing loss syndrome; Camptodactyly–tall stature–scoliosis–hearing loss syndrome.

Data provenance. Nearly all published knowledge of CATSHL derives from a small number of aggregated pedigree/case reports in the peer-reviewed literature (not large-scale EHR or registry data), supplemented by animal-model studies (mouse and zebrafish Fgfr3 loss-of-function models) that established the underlying mechanism before and alongside the human descriptions.

2. Etiology

Primary cause — genetic (monogenic). CATSHL is caused by heterozygous (autosomal dominant) or, more rarely, homozygous (autosomal recessive) missense loss-of-function mutations in FGFR3, the gene encoding a receptor tyrosine kinase that normally acts as a negative regulator of bone growth in the cartilage growth plate Colvin et al., 1996, Nat Genet 12:390-397, PMID:8630492; Deng et al., 1996, Cell, PMID:8601314.

Genetic risk factors / causal variants identified to date:

All are located in/near the tyrosine kinase domain of FGFR3 and are functionally characterized as reducing (R621H, partial loss) or abolishing receptor kinase activity, in contrast to the gain-of-function substitutions (e.g., G380R, K650E) that cause achondroplasia/thanatophoric dysplasia at other FGFR3 residues.

Environmental/lifestyle risk factors: None identified — CATSHL is a purely monogenic condition; no environmental, infectious, or lifestyle contributors have been reported.

Protective factors: None specifically documented. No modifier genes or protective alleles are reported in the literature to date.

Gene-environment interaction: Not applicable/not studied — this is a fully penetrant single-gene disorder with no reported environmental modulation.

3. Phenotypes

Core tetrad

1. Camptodactyly — permanent, irreducible flexion of one or more fingers and/or toes (HPO: HP:0012385, Camptodactyly, or the more general HP:0002813, Abnormality of joint mobility)
2. Tall stature — postnatal-onset overgrowth, disproportionate to family background (HPO: HP:0000098, Tall stature)
3. Scoliosis / chest-wall anomalies — scoliosis and/or pectus excavatum (HPO: HP:0002650 Scoliosis; HP:0000767 Pectus excavatum)
4. Sensorineural hearing loss — bilateral, with absent otoacoustic emissions, congenital or early-infancy onset, variably progressive, ranging mild–severe (HPO: HP:0000407, Sensorineural hearing impairment; HP:0008625, Bilateral sensorineural hearing impairment)

Additional reported phenotypes

• Microcephaly in a subset of patients (HPO: HP:0000252)
• Developmental delay / intellectual disability — reported in some patients, notably the more severely affected Egyptian brother (IQ ~70) in the homozygous T546K family (HPO: HP:0001263 Developmental delay; HP:0001249 Intellectual disability)
• Severe lateral tibial deviation, arachnodactyly, and inability to ambulate in the severe homozygous (recessive) presentation (Makrythanasis et al. 2014)
• Peg-shaped incisors — newly described in the 2024 Italian family with p.Arg621Cys, a feature overlapping with LADD (Lacrimo-Auriculo-Dento-Digital) syndrome, another FGFR3-spectrum condition — representing a phenotypic expansion of CATSHL Cannova et al. 2024, PMID:37990933
• Lower-limb joint abnormalities

Phenotype characteristics

• Onset: Tall stature typically becomes apparent postnatally/in childhood; hearing loss is congenital or manifests in early infancy; camptodactyly is present from early life.
• Severity/course: Hearing loss is variably progressive in early childhood; overall severity is markedly worse in the homozygous/biallelic (recessive) form (inability to walk, more pronounced skeletal deformity, intellectual disability) than in the heterozygous dominant form.
• Frequency among affected individuals: Camptodactyly, tall stature, and hearing loss are present in essentially all reported/genetically confirmed cases (definitional); scoliosis/pectus excavatum, microcephaly, and intellectual disability are variable/less penetrant secondary features.
• Quality of life impact: Not formally studied with standardized instruments (no EQ-5D/SF-36 data identified); clinically, hearing loss and orthopedic/mobility impairment (particularly in the recessive form) are the primary functional burdens.

4. Genetic/Molecular Information

• Causal gene: FGFR3 (Fibroblast Growth Factor Receptor 3), HGNC gene, OMIM 134934, chromosome 4p16.3*.
• Variant classification: All reported CATSHL variants are missense, classified as pathogenic/likely pathogenic loss-of-function or partial-loss-of-function alleles (ACMG/AMP framework); ClinVar entries exist for c.1637C>A (p.Thr546Lys) ClinVar RCV000144699 and for the R621H/R621C tyrosine-kinase-domain substitutions.
• Variant type: All missense substitutions clustered in or near the tyrosine kinase domain — distinct from the extracellular Ig-like/transmembrane domain hotspots (e.g., G380R) that cause the gain-of-function achondroplasia spectrum.
• Somatic vs. germline: All reported CATSHL variants are germline; no somatic CATSHL cases reported (unlike some FGFR3 gain-of-function conditions, which can also arise somatically in certain skin/bladder neoplasms — not relevant here).
• Functional consequence: Loss of function / partial loss of function of FGFR3 kinase activity. Because FGFR3 is normally an inhibitory (negative) regulator of chondrocyte proliferation/differentiation and bone growth, its functional inactivation derepresses growth-plate chondrogenesis, producing skeletal overgrowth — the inverse of achondroplasia's growth suppression from constitutive receptor activation. The dominant R621H allele behaves as a partial loss-of-function/possible dominant-negative allele sufficient to cause disease in the heterozygous state, whereas T546K requires biallelic (homozygous) loss for full clinical expression — heterozygous T546K carriers (parents, unaffected sister) are clinically unaffected, indicating a milder functional deficit per allele than R621H.
• Allele frequency: These are private, rare familial variants; not appreciable in population databases such as gnomAD (consistent with disease-causing rarity).
• Modifier genes: None established; the recessive vs. dominant difference between T546K and R621H appears to reflect differing residual kinase activity of each specific substitution rather than a separate modifier locus.
• Epigenetics/chromosomal abnormalities: None reported — CATSHL is caused by point mutations, not by copy-number, translocation, or epigenetic mechanisms.

5. Environmental Information

No environmental, infectious, occupational, or lifestyle contributing factors have been identified or hypothesized for CATSHL syndrome in the literature; it is presented uniformly as a monogenic Mendelian condition with full genetic causation.

6. Mechanism / Pathophysiology

Molecular pathway and causal chain

FGFR3 is a receptor tyrosine kinase highly expressed in the proliferative and prehypertrophic zones of the cartilage growth plate, as well as in the cochlea, brain, and spinal cord. In the growth plate, ligand-activated FGFR3 signals principally through the MAPK/ERK cascade (and secondarily PI3K/AKT, PKCγ, and STAT1) to inhibit chondrocyte proliferation and hypertrophic differentiation, thereby restraining endochondral bone elongation — i.e., FGFR3 is physiologically a negative regulator of bone growth Colvin et al. 1996, PMID:8630492; Deng et al. 1996, Cell, PMID:8601314.

• In achondroplasia/thanatophoric dysplasia, gain-of-function FGFR3 mutations hyperactivate this inhibitory MAPK signal → excess growth suppression → short-limbed dwarfism.
• In CATSHL, loss-of-function FGFR3 mutations reduce MAPK-mediated inhibition of chondrocyte proliferation/hypertrophy → disinhibited endochondral growth → tall stature and long-bone/vertebral overgrowth. Conditional chondrocyte-specific Fgfr3 knockout mice show markedly lengthened growth plates, increased osteoblast number, and increased bone formation and bone mass.
• Postnatal Fgfr3 deletion in chondrocytes also produces chondroma-like lesions (enchondromas/osteochondromas) adjacent to disordered growth plates, associated with decreased ERK activity and upregulated Indian hedgehog (IHH) signaling; pharmacologic IHH-pathway inhibition reduced lesion occurrence in Fgfr3-deficient mice, implicating derepressed Hedgehog signaling as a downstream driver of the skeletal dysplasia phenotype Zhou et al. 2015, PLOS Genetics, PMID (Zhou/Wen/Chen et al.); doi:10.1371/journal.pgen.1005214.
• A zebrafish CRISPR/Cas9 fgfr3 loss-of-function model (frameshift mutations in the tyrosine-kinase domain) recapitulated microcephaly, craniofacial dysmorphism (domed skull, mandibular deformity), delayed endochondral and intramembranous ossification, chondroma-like growth-plate lesions, and abnormal chondrocyte hypertrophy — and demonstrated enhanced canonical Wnt/β-catenin signaling alongside increased IHH signaling as a partial molecular driver; pharmacologic Wnt/β-catenin inhibition (XAV939) partially rescued the chondrocyte/craniofacial phenotype, suggesting a therapeutic pathway target Sun X. et al. 2020, Theranostics 10(16):7111-7130, PMID:32641982.

Hearing loss mechanism

FGFR3 is expressed from approximately embryonic day 16 in the mouse cochlear duct in a domain that gives rise to pillar cells, outer hair cells, and Deiters' cells, and becomes restricted to pillar cells by birth. FGF8 signals from inner hair cells to FGFR3-expressing supporting cells to drive pillar-cell differentiation. Fgfr3-null mice show failure of pillar cell differentiation and failure of tunnel-of-Corti formation, with two rows of undifferentiated cells persisting in the pillar-cell region, altered pillar-cell innervation/fiber-guidance, and profound deafness — establishing FGFR3 loss-of-function as directly causal for the inner-ear phenotype, mirroring the human sensorineural hearing loss in CATSHL Colvin et al. 1996, PMID:8630492; Puligilla et al./Mueller et al., FGFR3 pillar cell studies, J Neurosci 22(21):9368; Hayashi et al. 2007, Dev Dyn, "Loss of Fgfr3 leads to excess hair cell development in the mouse organ of Corti". Downstream transcription factors Etv4/Etv5/Etv1 appear to act as key FGFR3-dependent regulators of pillar-cell identity. This contrasts with the reciprocal FGFR3 gain-of-function mouse model (activating Y367C mutation, modeling Muenke/achondroplasia-spectrum craniosynostosis), which also causes hearing loss but via excessive FGF signaling and altered pillar/Deiters cell ratios — indicating that both too little and too much FGFR3 signaling disrupt normal organ of Corti patterning [PMID:19073250].

Causal chain summary

FGFR3 loss-of-function variant (germline) → reduced receptor tyrosine kinase activity → diminished inhibitory MAPK/ERK signaling in growth-plate chondrocytes + derepressed IHH and Wnt/β-catenin signaling → disinhibited chondrocyte proliferation/hypertrophy and endochondral ossification → long-bone/vertebral overgrowth (tall stature), joint contractures (camptodactyly), spinal curvature (scoliosis); in parallel, loss of FGFR3-dependent FGF8 signal transduction in cochlear supporting cells → failure of pillar cell differentiation/tunnel of Corti formation → sensorineural hearing loss.

Suggested ontology terms

• GO (biological process): GO:0007173 (epidermal growth factor receptor signaling pathway analog)/more precisely GO:0008543 (fibroblast growth factor receptor signaling pathway); GO:0060445 (branching involved in salivary gland morphogenesis – not relevant); relevant terms: GO:0060563 (Deiters' cell differentiation-adjacent), GO:0003417 (growth plate cartilage chondrocyte growth), GO:0061036 (positive regulation of cartilage development), GO:0021940 (positive regulation of cerebellar granule cell precursor proliferation – not relevant); most directly: GO:0008543 (fibroblast growth factor receptor signaling pathway), GO:0061181 (regulation of chondrocyte development), MAPK cascade GO:0000165.
• GO (molecular function): GO:0005007 (fibroblast growth factor-activated receptor activity), GO:0004713 (protein tyrosine kinase activity)
• GO (cellular component): GO:0005886 (plasma membrane), GO:0043235 (receptor complex)
• CL (cell types): CL:0000138 (chondrocyte), CL:0000743 (hypertrophic chondrocyte), pillar cell (organ of Corti; CL term for inner/outer pillar cell), CL:0002261 (Deiters' cell / cochlear supporting cell), CL:0000062 (osteoblast)

7. Anatomical Structures Affected

Organ level: - Skeletal system: long bones (femur, tibia), vertebral column (scoliosis), phalanges/digits (camptodactyly), thoracic cage (pectus excavatum) — primary - Inner ear/cochlea: organ of Corti — primary - CNS: brain (microcephaly in a subset) — secondary - Body systems involved: musculoskeletal, auditory, and (variably) nervous system

Tissue/cell level: - Cartilage/growth plate — chondrocytes (proliferative and hypertrophic zones) — UBERON: growth plate cartilage - Bone — osteoblasts, endochondral and intramembranous ossification centers - Organ of Corti — pillar cells, Deiters' cells, outer hair cells, inner hair cells (Cell Ontology terms as above)

Subcellular level: FGFR3 is a plasma membrane receptor tyrosine kinase (GO:0005886); downstream effectors act in the cytoplasm (MAPK/ERK cascade components) and nucleus (transcriptional targets such as Etv4/5/1, and IHH/Wnt-β-catenin pathway effectors).

Localization/laterality: Skeletal overgrowth and camptodactyly are typically bilateral (may be asymmetric in digit involvement); hearing loss is bilateral sensorineural.

Relevant UBERON terms: UBERON:0002391 (cartilage of epiphysis / growth plate — approximate), UBERON:0001690 (ear), UBERON:0004674 (organ of Corti / spiral organ), UBERON:0002228 (rib cage / thoracic skeleton), UBERON:0002101 (limb).

8. Temporal Development

• Onset: Congenital/early-infancy onset of hearing loss; tall stature emerges as a postnatal growth pattern typically evident in childhood; camptodactyly present from early life; scoliosis often develops/becomes apparent during growth (childhood/adolescence).
• Onset pattern: Insidious/developmental rather than acute.
• Progression: Hearing loss is described as variably progressive in early childhood, ranging from mild to severe by later assessment; skeletal overgrowth and scoliosis progress with growth and may stabilize post-puberty (as in other overgrowth syndromes), though formal longitudinal natural-history data are not established in the literature reviewed.
• Disease course: Chronic, lifelong; no spontaneous remission reported. No mortality has been attributed to CATSHL in the literature to date — prognosis for survival is considered favorable.
• Severity gradient over time: The recessive (homozygous T546K) presentation is more severe and disabling from an early age (loss of ambulation) than the dominant (heterozygous R621H/R621C) presentation.

9. Inheritance and Population

• Inheritance pattern: Predominantly autosomal dominant (heterozygous R621H, R621C); rarely autosomal recessive (homozygous T546K in a consanguineous family, with unaffected heterozygous carrier parents/sibling) [Makrythanasis et al. 2014].
• Penetrance: Appears high/complete for the dominant form within the reported Utah pedigree (affected individuals across 4–7 generations); the recessive T546K allele is essentially non-penetrant in the heterozygous state (unaffected carrier parents and sister), consistent with a true recessive, dosage-dependent mechanism.
• Expressivity: Variable — severity (ambulation, intellectual disability, degree of hearing loss) differs between the dominant and recessive forms and even between siblings (e.g., the two Egyptian brothers differed in severity, with the older being unable to walk and having mild intellectual disability).
• Genetic anticipation: Not reported.
• Germline mosaicism: Not reported in the literature reviewed.
• Founder effects/consanguinity: The recessive T546K case arose in a consanguineous Egyptian family, illustrating the classic mechanism by which a rare recessive allele can become homozygous; no broader founder-population data.
• Carrier frequency: Not established (each identified variant is a private/family-specific finding, not present at appreciable frequency in population databases such as gnomAD).

Population demographics/epidemiology: - Extreme rarity: As of the most recent literature reviewed, approximately 30 documented individuals worldwide — the original 27 living affected members of the 4-generation (35 total across 7-generation) Utah pedigree [Toydemir et al. 2006], 2 brothers from a consanguineous Egyptian family [Makrythanasis et al. 2014], and most recently 2 additional affected individuals (father and daughter) from an Italian family with a novel variant [Cannova et al. 2024]. No formal population prevalence or incidence estimate exists (Orphanet lists it in the "not yet documented"/single-family-reported prevalence class). - Geographic distribution: Cases reported from the United States (Utah), Egypt, and Italy — no evidence of a specific endemic region; likely reflects ascertainment of individual pedigrees rather than a true geographic pattern. - Sex ratio: No skewed sex ratio reported (autosomal inheritance; both sexes affected in all reported families). - Age distribution: All age groups from childhood through adulthood represented across the reported pedigrees, consistent with a lifelong, non-lethal condition.

10. Diagnostics

Clinical recognition: Diagnosis is suspected clinically from the combination of postnatal-onset tall stature, camptodactyly, scoliosis/pectus excavatum, and bilateral sensorineural hearing loss with absent otoacoustic emissions, particularly in the setting of a compatible family history (autosomal dominant transmission across generations, or consanguinity for the recessive form).

Confirmatory genetic testing: - Single-gene FGFR3 sequencing (Sanger or targeted next-generation sequencing) of the tyrosine kinase domain exons is the definitive diagnostic test, as performed in all published cases (identification of R621H, T546K, R621C). - Gene panels for skeletal dysplasia/overgrowth or for syndromic hearing loss that include FGFR3 would be expected to capture CATSHL variants (per commercial genetic testing registries, e.g., NIH GTR listing for "Camptodactyly-tall stature-scoliosis-hearing loss syndrome," condition C1864852) NIH GTR. - Exome sequencing was the discovery method for the recessive T546K family (Makrythanasis et al. 2014), confirmed by Sanger sequencing and segregation analysis. - Audiometry/otoacoustic emissions testing to characterize and monitor the sensorineural hearing loss. - Skeletal radiographs to assess long-bone length, vertebral alignment (scoliosis), and joint contractures.

Differential diagnosis: Other overgrowth syndromes (e.g., Marfan syndrome, Sotos syndrome, homocystinuria) and other syndromic sensorineural hearing loss conditions should be considered; the co-occurrence of tall stature with hearing loss (rather than short stature, which characterizes the far more common FGFR3 gain-of-function conditions) is the key distinguishing clue toward FGFR3 loss-of-function/CATSHL. The 2024 Italian family report also highlights phenotypic overlap with LADD syndrome (another FGFR3-related condition) via a shared dental finding (peg-shaped incisors), underscoring the importance of molecular confirmation.

Screening: No population-based or newborn screening program exists for this ultra-rare condition; diagnosis relies on clinical suspicion and targeted/family-based genetic testing.

11. Outcome/Prognosis

• Survival/mortality: No CATSHL-attributable deaths have been reported in the literature reviewed; life expectancy appears unaffected.
• Morbidity: Primary functional morbidity relates to (a) sensorineural hearing loss (variable severity, potentially requiring amplification) and (b) orthopedic/mobility impact of severe skeletal deformity, most pronounced in the recessive (homozygous) form, where the more severely affected sibling was unable to walk.
• Neurodevelopmental outcome: Developmental delay/intellectual disability is reported in a subset, more prominently associated with the recessive form (IQ ~70 in the more severely affected Egyptian brother) than clearly established for the dominant form.
• Prognostic factors: Zygosity/allele appears to be the principal prognostic determinant identified to date — biallelic (homozygous) loss-of-function produces a substantially more severe phenotype than monoallelic (heterozygous) loss-of-function, consistent with a dosage-dependent mechanism.
• Quality of life: Not formally quantified with standardized instruments in the literature reviewed.

12. Treatment

There is no disease-modifying or curative therapy for CATSHL syndrome; management is symptomatic and supportive, informed by general principles for the component features:

• Hearing rehabilitation: Hearing aids for mild-to-severe sensorineural hearing loss with adequate speech discrimination; cochlear implantation would be a consideration for severe/profound loss, by analogy with management of other syndromic sensorineural hearing loss conditions, though CATSHL-specific implantation outcome data were not identified in the literature reviewed. (NCIT: NCIT:C15302 general rehabilitative care; hearing-aid fitting and cochlear implantation are standard-of-care interventions for sensorineural hearing loss broadly.)
• Orthopedic management: Monitoring and, where indicated, surgical correction of scoliosis (NCIT:C15329, Surgical Procedure / orthopedic spinal surgery) and management of joint contractures/camptodactyly (splinting, physical therapy — NCIT:C15302, Physical Therapy) and severe lower-limb deformity (as in the recessive Egyptian family, where severe tibial deviation contributed to loss of ambulation).
• Developmental/educational support: For patients with developmental delay/intellectual disability, standard early-intervention and educational support services.
• Genetic counseling: Recommended given autosomal dominant (typically) or, less commonly, autosomal recessive inheritance, particularly relevant for consanguineous families (NCIT:C15240, Genetic Counseling).
• Experimental/mechanistic leads (preclinical only): Animal-model studies suggest that pharmacologic modulation of downstream pathways disinhibited by FGFR3 loss — Hedgehog/IHH pathway inhibition (PLOS Genetics 2015 mouse study) and Wnt/β-catenin inhibition (XAV939) (zebrafish 2020 study) — can partially rescue chondrocyte/skeletal phenotypes in model systems, representing potential future therapeutic targets, but these have not been tested in human CATSHL patients and no clinical trials for CATSHL specifically were identified.

No NCT-registered clinical trials specific to CATSHL syndrome were identified in this research; existing FGFR3-targeted therapeutics in clinical development (e.g., FGFR3 inhibitors, CNP-pathway analogs such as vosoritide) are designed for the opposite (gain-of-function, achondroplasia-spectrum) mechanism and are not applicable to CATSHL's loss-of-function pathophysiology.

13. Prevention

No primary, secondary, or tertiary prevention strategies exist beyond genetic counseling and prenatal/preimplantation genetic diagnosis for known familial variants in families with an established diagnosis, given the Mendelian (dominant or recessive) inheritance pattern. No immunization, screening program, or public-health intervention is applicable to this monogenic skeletal/auditory disorder.

14. Other Species / Natural Disease

No naturally occurring CATSHL-like disease has been reported in veterinary/companion-animal or wildlife populations in the literature reviewed. All non-human data derive from engineered laboratory models (see Section 15) rather than spontaneously occurring animal disease. FGFR3 is highly conserved between human and mouse, supporting cross-species mechanistic relevance, but no OMIA (Online Mendelian Inheritance in Animals) entry for a natural CATSHL-equivalent condition was identified.

15. Model Organisms

Phenotype recapitulation: The mouse and zebrafish Fgfr3 loss-of-function models recapitulate the core CATSHL triad of skeletal overgrowth, joint/growth-plate cartilage abnormality, and hearing impairment (via pillar-cell/organ-of-Corti defects) quite faithfully, and were instrumental in establishing FGFR3 loss-of-function as the causal mechanism — notably, the mouse phenotype was described a decade before the first human CATSHL family was reported, and the human discovery (Toydemir et al. 2006) explicitly drew on the mouse model to nominate FGFR3 as the candidate gene.

Model limitations: The zebrafish model captures craniofacial/microcephaly features not well recapitulated in mouse, but zebrafish skeletal architecture and organ of Corti biology differ substantially from human, limiting direct translational inference; mouse constitutive knockouts have reduced viability, complicating adult-phenotype study, motivating the shift to conditional/chondrocyte-specific models.

Applications: These models have been used to dissect the downstream signaling (MAPK/ERK, IHH/Hedgehog, Wnt/β-catenin) disinhibited by FGFR3 loss, and to test small-molecule pathway modulators (IHH inhibitors, XAV939) as proof-of-concept for future therapeutic strategies.

Summary of Key Evidence Citations

• Toydemir RM, Brassington AE, Bayrak-Toydemir P, et al. "A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome." Am J Hum Genet. 2006;79(5):935-941. PMID:17033969.
• Makrythanasis P, Temtamy S, Aglan MS, et al. "A Novel Homozygous Mutation in FGFR3 Causes Tall Stature, Severe Lateral Tibial Deviation, Scoliosis, Hearing Impairment, Camptodactyly, and Arachnodactyly." Hum Mutat. 2014;35:959-963.
• Cannova S, et al. "CATSHL syndrome, a new family and phenotypic expansion." Clin Genet. 2024;105:313-316. PMID:37990933.
• Colvin JS, Bohne BA, Harding GW, McEwen DG, Ornitz DM. "Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3." Nat Genet. 1996;12:390-397. PMID:8630492.
• Deng C, Wynshaw-Boris A, Zhou F, Kuo A, Leder P. "Fibroblast growth factor receptor 3 is a negative regulator of bone growth." Cell. 1996. PMID:8601314.
• Zhou X, et al. "FGFR3 Deficiency Causes Multiple Chondroma-like Lesions by Upregulating Hedgehog Signaling." PLOS Genetics. 2015. doi:10.1371/journal.pgen.1005214.
• Sun X, et al. "Fgfr3 mutation disrupts chondrogenesis and bone ossification in zebrafish model mimicking CATSHL syndrome partially via enhanced Wnt/β-catenin signaling." Theranostics. 2020;10(16):7111-7130. PMID:32641982.
• OMIM #610474 — CAMPTODACTYLY, TALL STATURE, AND HEARING LOSS SYNDROME.
• Orphanet ORPHA:85164 — Camptodactyly-tall stature-scoliosis-hearing loss syndrome.

Note on evidence gaps: No CATSHL-specific quality-of-life instrument data, no dedicated natural-history study, no CATSHL-specific clinical trial, and no naturally occurring veterinary disease model were identified — these represent open areas where the literature is silent rather than negative.

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Unresolved references

These identifiers did not resolve to a record and may be fabricated. A lookup that failed for transport reasons is indistinguishable from one that failed because the record does not exist, so spot-check before acting on them:

• DOI:10.1371/journal.pgen.1005214](https://journals.plos.org/plosgenetics/article (1 mention) - Identifier did not resolve to a record

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• CL:0002261 (1 mention) - the report calls it "Deiters' cell / cochlear supporting cell"; CL calls it endothelial cell of viscerocranial mucosa
• UBERON:0002391 (1 mention) - the report calls it "cartilage of epiphysis / growth plate — approximate"; UBERON calls it lymph
• UBERON:0004674 (1 mention) - the report calls it "organ of Corti / spiral organ"; UBERON calls it facial nerve root
• UBERON:0002228 (1 mention) - the report calls it "rib cage / thoracic skeleton"; UBERON calls it rib

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• GO:0007173 (1 mention) - the report calls it "epidermal growth factor receptor signaling pathway analog"; GO calls it epidermal growth factor receptor signaling pathway
• GO:0060445 (1 mention) - the report calls it "branching involved in salivary gland morphogenesis – not relevant"; GO calls it branching involved in salivary gland morphogenesis
• GO:0005007 (1 mention) - the report calls it "fibroblast growth factor-activated receptor activity"; GO calls it fibroblast growth factor receptor activity, and lists "fibroblast growth factor-activated receptor activity" among its other names
• GO:0043235 (1 mention) - the report calls it "receptor complex"; GO calls it signaling receptor complex, and lists "receptor complex" among its other names

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA.